Fresh analysis indicates that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Findings released in a prominent health publication demonstrates that while overweight individuals often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such drugs must be informed of the danger of rapid weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight in about one and a half years.
Comparing Approaches
The study, which reviewed 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
Scientists note that people who lose weight through dieting typically see a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors suggest the way of the drugs accounts for the amplified regain.
The injections imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making binge eating a significant risk."
A Chronic Condition?
Medical guidelines advise the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who state that the results "emphasize the long-term character of obesity," akin to managing conditions like high blood pressure.
User Accounts
People who have come off the jabs explain a intense resurgence of cravings.
"I experienced something activating and you become extremely hungry," described one woman.
This difficulty is compounded if users have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data show that a significant number of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is more common among females than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while the jabs are effective agents for shedding pounds, they are not a permanent cure and lasting health benefits hinges on combined behavioural support.